Pipeline

A Pipeline of Differentiated Oncology Candidates

Engineered toxin bodies (ETBs) are differentiated biologic therapies with unique properties. Single agent activity and tolerability have been observed with ETB therapy in heavily relapsed/refractory patients.

Program	Indication (Target)	Preclinical	Phase 1	Phase 2	Phase 3
MT-6402	Multiple - solid tumors (PD-L1)	Preclinical Phase complete	Phase 1 Phase in progress	Phase 2 Phase not started	Phase 3 Phase not started
MT-5111	Multiple - solid tumors (HER2)	Preclinical Phase complete	Phase 1 Phase in progress	Phase 2 Phase not started	Phase 3 Phase not started
MT-0169	Multiple Myeloma (CD38)	Preclinical Phase complete	Phase 1 Phase in progress	Phase 2 Phase not started	Phase 3 Phase not started
CTLA-4	Multiple – solid tumors (CTLA-4)	Preclinical Phase in progress	Phase 1 Phase not started	Phase 2 Phase not started	Phase 3 Phase not started
TROP-2	Triple-negative MBC, NSCLC	Preclinical Phase in progress	Phase 1 Phase not started	Phase 2 Phase not started	Phase 3 Phase not started
TIGIT	Multiple - solid tumors	Preclinical Phase in progress	Phase 1 Phase not started	Phase 2 Phase not started	Phase 3 Phase not started
BCMA	Multiple Myeloma	Preclinical Phase in progress	Phase 1 Phase not started	Phase 2 Phase not started	Phase 3 Phase not started
SLAMF-7	Multiple Myeloma (SLAMF-7)	Preclinical Phase in progress	Phase 1 Phase not started	Phase 2 Phase not started	Phase 3 Phase not started

Completed

In-progress

Planning

MT-6402

3rd-Generation ETB Targeting PD-L1

MT-6402 is an ETB candidate designed to induce potent anti-tumor effects via PD-L1 targeting through multiple mechanisms that may overcome the limitations of the PD-L1 antibodies. The IND for MT-6402 was accepted in January 2021 and a Phase 1 study of MT-6402 in PD-1/PD-L1 antibody relapsed/refractory patients initiated in July 2021.

View Candidate

MT-5111

2nd-Generation ETB Targeting HER2

MT-5111 is an ETB candidate that has been shown pre-clinically to bind and kill HER2 expressing cells in a way that is consistent with SLTA mediated cellular cytotoxicity. MT-5111 is designed to avoid competition with other HER2 targeted agents and overcome the mechanisms of tumor resistance to current HER2 targeted therapies. MT-5111 is currently in a first-in-human Phase 1 dose-escalation study of patients with HER2+ solid tumors and the HER2- positive breast cancer expansion cohort initiated as of November 2021. Dose escalation will continue to determine the recommended Phase 2 dose while the breast cancer expansion cohort collects efficacy and safety data.

View Candidate

MT-0169

2nd-Generation ETB Targeting CD38

MT-0169 is an ETB candidate that has been shown pre-clinically to bind and kill CD38 expressing cells in a way that is consistent with SLTA mediated cellular cytotoxicity. MT-0169 is currently in a first-in-human Phase 1 dose-escalation study of relapsed/refractory myeloma patients.

View Candidate

Next generation ETBs are in development for other targets, including CTLA-4, TIGIT, TROP2, SLAMF-7, CD20 and CD45.